Dedicated to the
Health and Welfare of All Cats
A A A
Font Size
education

Cat Health News Blog

A resource for dedicated cat supporters

Since its start in 2007, Cat Health News has featured the latest information on feline health. The bi-weekly blog is a mix of the most current published research from Winn-funded research and other sources. There are over 875 blog post items and more than 1,000 subscribers through the RSS feed.


icon-blogWinn-funded research is specifically noted by the small green cat.

  • Exploring use of itraconazole in treatment of FIP

    Jun 18, 2019
    Takano T, Akiyama M. et al.  Antiviral activity of itraconazole against type I feline coronavirus infection.  Vet Res 2019;50:5 DOI

    Researchers around the world are working intensively to find a safe and effective treatment for feline infectious peritonitis (FIP), a highly lethal systemic disease, but to date no such treatment has become available for practical use.  The etiologic agent in FIP is a coronavirus, an enveloped, single-stranded   positive-sense RNA virus.  Not all feline coronaviruses, however, cause FIP; only the feline infectious peritonitis virus (FIPV) biotype is the agent involved in FIP.  The other feline coronavirus biotype, feline enteric coronavirus (FECV), causes a mild, often subclinical, enteritis.  Both feline coronavirus (FCoV) biotypes exist as two serotypes, type I and II; therefore, there are FECV types I and II and FIPV types I and II.  The majority of FCoVs worldwide, approximately 70-90%, belong to type I.

    Previously these authors determined that type I FCoV has a close association with cholesterol throughout its life cycle, and that itraconazole, a highly lipophlic, triazole antifungal drug often used to treat dermatophytosis and other fungal infections in cats, inhibits FCoV infection. Itraconazole has been reported to inhibit intracellular cholesterol transport, and the authors wanted to determine if this drug would inhibit intracellular cholesterol transport in feline cells.  In the present study, the antiviral effects of itraconazole on FCoV were studied in cell cultures of feline cells found to be sensitive to types I and II FIPV and type II FECV.  Three strains of type I FIPV and one strain of type II FIPV were used in the study.

    Results of the study showed that itraconazole inhibits type I FCoV infection in feline cells, but had no effect on Type II FCoV infection. Based on the known pharmacokinetics of itraconazole in cats, and the results obtained with various concentrations of the drug in cell cultures evaluated in the present study, the authors recommend using itraconazole for treatment of FIP following the currently recommended fungal infection treatment protocol in cats.  The authors plan to perform a clinical trial of itraconazole in cats diagnosed with FIP, and also investigate combinations of itraconazole with other drugs in treatment of FIP. [PJS]

    See also:

    Takano T, Satomi Y. et al.  Differential effect of cholesterol on type I and type II feline coronavirus infection.  Arch Virol 2016;161:125-133.

    Takano T, Endoh M et al.  The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection.  Antiviral Res 2017;145:96-102.

    Kim Y, Liu H et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor.  PLoS Pathog 12:e1005531.


    biotype feline infectious peritonitis lipophilic serotype

    More on cat health:

    Winn Feline Foundation Library
    Find us on Facebook
    Follow us on Twitter
    Pin with us on Pinterest
    Join us on Google+

 

Archives

2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007